-

12:41:41 PM

FNA Stock News

FNA - Paragon 28 Inc

09/11/23 7:00 AM

NYSE : FNA

fda approval

Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System

Paragon 28, Inc., announced today they have received an Investigational Device Exemption approval from the FDA to commence a feasibility study for configurations of the SMART Total Talus™ System used in conjunction with the Paragon 28 ® APEX 3 D™ Total Ankle Replacement System. The study is expected to begin in early 2024.. This press release features...

RHEA-AI

very positive

08/28/23 4:05 PM

NYSE : FNA

conferences

Paragon 28 to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023, at 4:55 p.m. Eastern Time/ 2:55 p.m....

RHEA-AI

neutral

08/02/23 4:05 PM

NYSE : FNA

earnings

Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance

Consolidated net revenue for the six months ended June 30, 2023 was $103.0 million, representing 22.9% and 23.9% reported and constant currency growth, respectively, compared to the six months ended June 30, 2022. U.S. net revenue for the second quarter of 2023 and six months ended June 30, 2023 was $42.3 million and $87.2 million, respectively, representing...

RHEA-AI

neutral

07/28/23 8:00 AM

NYSE : FNA

conferences

Paragon 28 to Present at the Canaccord Genuity 43rd Annual Growth Conference

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:30 a.m. Eastern Time/ 6:30 a.m. Mountain Time.

RHEA-AI

neutral

07/12/23 4:05 PM

NYSE : FNA

conferencesearnings

Paragon 28 To Report Second Quarter Financial Results on August 2, 2023

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The company’ s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time/ 2:30 p.m. Mountain...

RHEA-AI

neutral

05/23/23 8:00 AM

NYSE : FNA

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Paragon 28, Inc. is pleased to announce the launch of its Gorilla ® Supramalleolar Osteotomy Plating and PRESERVE™ SMO Allograft System which were developed to provide surgeons versatility in plate selection and surgical approach for supramalleolar osteotomies. The system includes patent pending drilling and cutting guides to facilitate repeatable...

RHEA-AI

neutral

05/04/23 4:05 PM

NYSE : FNA

earnings

Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue guidance. Consolidated net revenue for the first quarter of 2023 was a record $52.0 million, representing 25.8% and 27.1% reported and...

RHEA-AI

neutral

04/26/23 4:05 PM

NYSE : FNA

conferences

Paragon 28 to Present at the Bank of America Securities 2023 Healthcare Conference

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 5:20 p.m. Eastern Time/ 3:20 p.m. Mountain...

RHEA-AI

neutral

04/24/23 4:05 PM

NYSE : FNA

Paragon 28 Launches Phantom® Metatarsal Shortening System

Paragon 28, Inc., is pleased to announce the launch of its Phantom ® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of the lesser metatarsals. Mark Myerson, MD, Phantom ® design surgeon, said, "Many implants are re-iterations of existing products, however the Phantom ®...

RHEA-AI

neutral

04/20/23 4:05 PM

NYSE : FNA

conferencesearnings

Paragon 28 To Report First Quarter Financial Results on May 4, 2023

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2023 after market close on Thursday, May 4, 2023. The company’ s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time/ 2:30 p.m. Mountain Time.

RHEA-AI

neutral

FNA Data

IndustrySurgical and Medical Instrument Manufacturing
Websiteparagon28.com
Security nameParagon 28 Inc
SectorManufacturing
CountryUS

About Paragon 28 Inc

paragon 28 was established in 2010 as an orthopedic foot and ankle company. the name “paragon 28” was chosen to show that we are exclusively a foot and ankle company, with the “28” representing the number of bones in the foot. we will remain true to that vision. paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. our mission is to strategically build a company around the core principles that drive innovation and quality. relentlessly working to advance the science behind foot and ankle surgery, paragon 28 is passionate about and committed to: - creation and innovation: blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - a focus on service: a customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - efficient practices: meeting the needs of increasing pricing pressures and reimbursemen